Table 2.
Change from baseline to week 6 on efficacy measures (intent-to-treat population).
| Outcome measure | Lurasidone 20 mg/day(n = 71) | Lurasidone 40 mg/day(n = 65) | Lurasidone 80 mg/day(n = 70) | Haloperidol 10 mg/day(n = 72) | Placebo(n = 71) |
|---|---|---|---|---|---|
| BPRS | |||||
| LS mean change (SE) | −5.0 (1.4) | −5.2 (1.4) | −8.0 (1.4) | −9.8 (1.4) | −7.9 (1.4) |
| p value versus placebo | 0.357 | 0.437 | 0.999 | 0.747 | — |
| PANSS | |||||
| LS mean change (SE) | −7.1 (2.3) | −7.2 (2.4) | −13.6 (2.3) | −16.0 (2.3) | −12.3 (2.3) |
| p value versus placebo | 0.109 | 0.126 | 0.694 | 0.252 | — |
| CGI-S | |||||
| LS mean change (SE) | −0.5 (0.1) | −0.4 (0.1) | −0.8 (0.1) | −0.8 (0.1) | −0.7 (0.1) |
| p value versus placebo | 0.179 | 0.128 | 0.595 | 0.463 | — |
| MADRS | |||||
| LS mean change (SE) | −1.3 (0.97) | −1.1 (1.0) | −2.5 (0.98) | −2.7 (0.96) | −1.9 (0.97) |
| p value versus placebo | 0.620 | 0.565 | 0.668 | 0.562 | — |
BPRS, brief psychiatric rating scale; CGI-S, clinical global impression-severity; LS, least squares; MADRS, Montgomery–Åsberg depression rating scale; PANSS, positive and negative syndrome scale; SE, standard error.